NCT06240403 is a Phase 2 clinical trial of Digoxin 0.125 MG in Heart Failure, Systolic, sponsored by University of Leeds.

Who is sponsoring NCT06240403?

NCT06240403 is sponsored by University of Leeds.

What drugs are being tested in NCT06240403?

Interventions in NCT06240403: Digoxin 0.125 MG.

What condition does NCT06240403 study?

NCT06240403 studies Heart Failure, Systolic, Diabetes Mellitus, Type 2.

Is NCT06240403 still recruiting?

NCT06240403 is currently not yet recruiting. Last updated 6 December 2024.

Last reviewed 2024-12-06 · How we verify

NCT06240403

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

Not yet recruiting Phase 2 Last updated 6 December 2024

What this trial tests

Phase 2 trial testing Digoxin 0.125 MG in Heart Failure, Systolic in 100 participants. Not yet recruiting.

Timeline

1 September 2025

Primary endpoint
28 August 2028

28 August 2029

Quick facts

Lead sponsor	University of Leeds
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 September 2025
Primary completion	28 August 2028
Estimated completion	28 August 2029
Sites	1 location across United Kingdom

Drugs / interventions tested

Digoxin 0.125 MG — full drug profile →

Conditions studied

Heart Failure, Systolic — all drugs for Heart Failure, Systolic →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

University of Leeds

Who can join

18 and older, any sex, with Heart Failure, Systolic or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In pilot studies the investigators have shown that subcutaneous adipose tissue (SAT) from patients with reduced ejection fraction heart failure (HFrEF) and type 2 diabetes mellitus (T2DM) is dysfunctional. Endothelial cells from the adipose tissue from these patients are senescent and have deleterious effects on healthy human subcutaneous adipocytes, including increasing expression of IL-6 (gene and protein) and reducing glucose uptake. Digoxin, a well-established treatment for HFrEF, selectively clears these senescent endothelial cells and prevents adipocyte dysfunction. This study will examine the effect of digoxin on adipose tissue on the burden of senescent cells.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances in Aging and Immunosenescence: Mechanisms and Therapeutic Strategies.
Wang S, Huo T, Lu M, Zhao Y, et al · · 2025 · cited 20× · PMID 40214453 · DOI 10.3390/cells14070499
Anti-senescence therapies: a new concept to address cardiovascular disease.
Stojanović SD, Thum T, Bauersachs J. · · 2025 · cited 9× · PMID 40036821 · DOI 10.1093/cvr/cvaf030
The role of cellular senescence in cardiovascular disease.
Xu C, Qiu Z, Guo Q, Huang Y, et al · · 2025 · cited 1× · PMID 41053058 · DOI 10.1038/s41420-025-02720-5
Repurposing of NKA inhibitors ('cardiac glycosides'): a critical analysis.
Evans K, Seifert R. · · 2026 · cited 1× · PMID 40679588 · DOI 10.1007/s00210-025-04443-x

Verify or expand the search:

Other recruiting trials for Heart Failure, Systolic

Currently open trials in the same condition.

NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT06336746 — Cardiac Performance During Steep Trendelenburg Position in Patients Undergoing Robotic Surgery Surgery. · recruiting
NCT06675552 — Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany · recruiting
NCT06332391 — Paced Heart Rate Acceleration for Cardiac Conditioning · NA · recruiting
NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting

Other University of Leeds trials

Trials by the same sponsor.

NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins · NA · not yet recruiting
NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain · NA · not yet recruiting
NCT07247812 — tSCS in Children and Young People With HCP · NA · not yet recruiting
NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
NCT06842654 — EORTC Quality of Life Measurement Strategies in Progressive Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06240403 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leeds
Last refreshed: 6 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06240403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing